Conservative groups, anti-abortion organizations, and members of the 'Make America Healthy Again' movement are advocating for 'restorative reproductive medicine' as an alternative to in vitro fertilization (IVF), complicating President Donald Trump's pledge to expand IVF access. Despite Trump's self-identification as 'the fertilization president' and an executive order in February to make IVF more affordable, the White House has not issued a policy to cover IVF services. Instead, federal actions—including a proposed grant for a holistic infertility training center, the layoff of the IVF success tracking team at HHS, and Arkansas becoming the first state to require insurance coverage for restorative reproductive medicine—signal a shift toward holistic approaches. Critics, including fertility specialists, warn that promoting restorative methods as morally superior undermines evidence-based care and may deny patients access to proven IVF treatments. The International Institute for Restorative Reproductive Medicine, which coined the term in the 1990s, has engaged with federal officials, and conservative think tanks like the Heritage Foundation have supported the movement. While proponents claim the approach is science-based and effective for some patients, experts argue it lacks formal recognition and may represent a politically motivated shift away from established medical practices.

A baby born from an embryo frozen for over 30 years marks a significant milestone in reproductive medicine. The child, Thaddeus, was conceived from an embryo stored since 1994 by Linda Archerd, who later facilitated its adoption through the Snowflakes program. The case highlights ethical debates around long-term embryo storage, adoption, and the societal implications of reproductive technology.

China has introduced a fertility subsidy program to combat historic low birth rates, offering cash incentives for first, second, and third children up to age three. The policy aims to ease childcare costs and prevent further population decline, which threatens China's economic and political stability. The country's total fertility rate (TFR) is below replacement level, and population growth has stagnated, with record declines in recent years.

The global Assisted Reproductive Technology (ART) market is projected to grow at a 6.1% CAGR from 2024-2031, reaching USD 53.7 billion by 2030 from USD 33.8 billion in 2022. The market report by DataM Intelligence analyzes growth drivers, challenges, and opportunities, including advancements in IVF, increasing infertility rates, and expanding access in emerging markets. Key players like Irvine Scientific, CooperSurgical Inc, and ART Fertility Clinics are highlighted, with the latter launching a TV ad emphasizing transparency and a 70% pregnancy success rate.

Cigna Healthcare is considering the launch of a fertility and family-building service with Carrot Fertility in Europe, expanding from a pilot program in the US. The initiative aims to support individuals through fertility treatments while navigating regulatory differences across global markets. The article also highlights challenges faced by UK expats and the role of employer support in international mobility.